Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for HIND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 7.018M
March 31, 2026 7.018M
December 31, 2025 5.919M
September 30, 2025 5.556M
June 30, 2025 0.656M
March 31, 2025 0.0333M
December 31, 2024 0.0592M
September 30, 2024 0.007M
June 30, 2024 0.5067M
March 31, 2024 0.4044M
December 31, 2023 0.4044M
September 30, 2023 0.0595M
June 30, 2023 0.0595M
March 31, 2023 0.0457M
December 31, 2022 0.009M
September 30, 2022 0.0001M
June 30, 2022 0.0001M
March 31, 2022 0.0001M
December 31, 2021 0.0001M
September 30, 2021 0.0061M
Date Value
June 30, 2021 0.0028M
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
March 31, 2020 0.0009M
December 31, 2019 0.0009M
September 30, 2019 0.0009M
June 30, 2019 0.0004M
March 31, 2019 0.0003M
December 31, 2018 0.0003M
September 30, 2018 0.0003M
June 30, 2018 0.0002M
March 31, 2018 0.0002M
December 31, 2017 0.0002M
September 30, 2017 0.0002M
June 30, 2017 0.0002M
March 31, 2017 0.0002M
December 31, 2016 0.0002M
September 30, 2016 0.00

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Cardiac Biotech Solutions, Inc. 170.44M
Anika Therapeutics, Inc. 13.38M
Enovis Corp. 57.67M
Edwards Lifesciences Corp. 576.60M
Perspective Therapeutics, Inc. 114.09M